AJ Bergman
Chief Financial Officer
Replay available
Capricor Therapeutics, Inc. (CAPR) Q3 2025 Earnings Call
Capricor Therapeutics, Inc. (NASDAQ: CAPR) Q3 2025 earnings conference call, held 2025-11-10. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Linda Marband
Chief Executive Officer
Ted Tenthoff
Analyst, Piper Sandler
Dylan Gershel
Analyst, Oppenheimer
Joseph Pontinas
Analyst, HC Wainwright
Kristen Kluska
Analyst, Cantor Fitzgerald
Catherine Novak
Analyst, Jones Trading
Madison Elsadi
Analyst, B. Riley Securities
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Capricor Therapeutics, Inc..
Replay transcript excerpt
WEBVTT 00:00:00.031 -- 00:00:04.335 Good afternoon, ladies and gentlemen, and welcome to the Capricorn Therapeutics third 00:00:04.335 -- 00:00:09.740 quarter 2025 conference call. At this time, all participants are in a listen-only 00:00:09.740 -- 00:00:14.384 mode. Following the presentation, we will conduct a question and answer session. 00:00:14.384 -- 00:00:18.868 If at any time during this call you require immediate assistance, please press star zero 00:00:18.868 -- 00:00:23.773 for the operator. This call is being recorded on Monday, November 10, 2025. 00:00:23.773 -- 00:00:25.294 I 00:00:25.294 -- 00:00:30.369 would now like to turn the conference over to our CFO, AJ Bergman, for the forward-looking 00:00:30.369 -- 00:00:33.350 statement. Please go ahead. 00:00:35.154 -- 00:00:37.496 Thank you very much, and good afternoon, everyone. 00:00:37.496 -- 00:00:41.099 Before we start, I would like to state that we will be making certain forward-looking 00:00:41.099 -- 00:00:45.583 statements during today's presentation. These statements may include statements regarding, 00:00:45.583 -- 00:00:50.468 among other things, the efficacy, safety, and intended utilization of our product candidates, 00:00:50.468 -- 00:00:54.792 our future R&D plans, including our anticipated conduct and timing of preclinical and 00:00:54.792 -- 00:00:59.669 clinical studies, our enrollment of patients in our clinical studies, plans to present 00:00:59.669 -- 00:01:04.798 or report additional data, plans regarding regulatory filings, potential regulatory developments 00:01:04.798 -- 00:01:09.287 involving our product candidates, potential regulatory inspections, revenue and reimbursement 00:01:09.287 -- 00:01:14.396 estimates, projected terms of definitive agreements, manufacturing capabilit...